Sign in

GLP-1 drugs for obesity

2021Big moment

The FDA approves semaglutide (Wegovy) for weight management; GLP-1 drugs produce large weight loss and become some of the best-selling medicines.

The story

On June 4, 2021, the U.S. Food and Drug Administration approved Wegovy, a weekly injection of semaglutide made by the Danish company Novo Nordisk, for chronic weight management in adults with obesity, or with overweight and a related condition. In the main trial, published in 2021, adults taking it lost about 15 percent of their body weight on average over 68 weeks, compared with about 2 percent on placebo, far more than any earlier drug. Later drugs such as tirzepatide, made by Eli Lilly, showed even larger effects, and the class became some of the best-selling medicines in the world.

GLP-1 is a hormone the gut releases after eating. It tells the pancreas to release insulin, slows the emptying of the stomach and signals fullness to the brain. Scientists including Svetlana Mojsov, Joel Habener and Jens Juul Holst worked out its role in the 1980s. The first GLP-1 drug for diabetes, exenatide, reached the market in 2005, and liraglutide followed. A major barrier was that natural GLP-1 breaks down within minutes, so chemists engineered long-lasting versions that last a week. Semaglutide was approved for diabetes in 2017 and then, at a higher dose, for obesity.

The approval signaled a shift in how obesity is treated: as a chronic disease that can be managed with drugs, not only with willpower, diet or surgery. In 2024 semaglutide gained a further indication after a trial found it lowered heart attacks and strokes in people with obesity and heart disease. Obstacles remain: high prices, supply shortages, side effects such as nausea, and the fact that most people regain weight if they stop the drug. Insurers and governments are still debating who should be covered, and researchers are studying whether these drugs help other conditions.

Why it mattered

  • GLP-1 drugs have changed how obesity is treated, with millions of people using them and with rivals racing to develop pills and stronger versions.
  • Evidence that they cut cardiovascular events led regulators to approve them for heart protection as well as weight loss.
  • Early research on household purchases found that families with a GLP-1 user spent less on groceries and snacks, a shift that food companies began to track.
  • The success made Novo Nordisk and Eli Lilly among the most valuable pharmaceutical companies and reshaped drug investment.

Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made

Community notes

Loading notes…

Learn more ranked by votes

BookJohann Hari
Magic Pill
Search Open Library
VideoSearch YouTube
how GLP-1 drugs like Wegovy work
Search YouTube